Stocks Health care CLYM
NASDAQ · Health careClimb Bio, Inc. (CLYM)
It posted a net loss of $57.6M. In fiscal 2025 capital spending exceeded operating cash flow by $54.5M. At June 30, 2026 it held $44.1M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 6, 2026.
What Climb Bio, Inc. does
Climb Bio, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker CLYM.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | n/a | -$59.9M | -$0.88 | -$54.5M |
| 2024 | n/a | -$73.9M | -$1.53 | -$15.6M |
| 2023 | n/a | -$35.1M | -$1.30 | -$20.6M |
| 2022 | n/a | -$45.2M | -$1.72 | n/a |
| 2021 | n/a | -$47.5M | -$4.24 | n/a |
| 2021 | n/a | -$20.7M | -$10.49 | n/a |
Latest SEC filings
What Climb Bio, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 3, 2026
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 14, 2026Other event 8-K
- August 6, 2026Quarterly report 10-Q · period to June 30, 2026
- August 6, 2026
- July 8, 2026Passive stake (5% or more) SCHEDULE 13G
- July 7, 2026Activist stake changed SCHEDULE 13D/A
- July 1, 2026
- June 12, 2026
- June 12, 2026
Questions about CLYM
What does Climb Bio, Inc. do?
Climb Bio, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker CLYM.
Is Climb Bio, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $57.6M.
When did Climb Bio, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 6, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the insider trade from September 17, 2026.
Similar companies
Follow CLYM
Get an email when Climb Bio, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Follow CLYM: get an email when it filesWhere the numbers come from
Financial figures are the values Climb Bio, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.